tirzepatide pure 10mg Tirzepatide

10.1136/gutjnl-2019-320204 Gut 197 WeiG

2003, 58 (9), B788791

Cell culture studies demonstrate that GLP3 exhibits differential potency across its three target receptors: it is approximately 8.9-fold more potent at the human GIP receptor (EC50: 0.0643 nM) compared to the endogenous GIP ligand, while showing reduced potency at GLP-1 receptors (0.4-fold, EC50: 0.775 nM) and glucagon receptors (0.3-fold, EC50: 5.79 nM) relative to their native hormones[3]

Effect of subcutaneous tirzepatide versus placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: The SURPASS-5 randomized clinical trial